Ƶ

T1D Stem Cell Success Story; Lilly's Discount Tirzepatide Vials; Stelo Now Available

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

A type 1 diabetes patient talked about her successful treatment with an currently in trials, noting that she hasn't needed insulin since last August. (Washington Post)

Eli Lilly said tirzepatide (Zepbound) are available for self-pay through LillyDirect, significantly expanding the supply for patients with obesity.

was similar for Korean adults 60 and older with type 2 diabetes whether they were on SGLT2 inhibitors versus the GLP-1 receptor agonist dulaglutide (Trulicity), a population-based cohort study suggested. (Annals of Internal Medicine)

The Menopause Society announced the launch of its new monthly series, which will address key issues about managing menopause.

Epic Research data indicated that older adults with diabetes were more likely to have average HbA1c values under 6.5% or over 8% in the 5 years prior to the diagnosis compared with diabetic patients without Alzheimer's.

Wall Street thinks semaglutide (Ozempic, Wegovy) of Medicare drug price negotiations in 2027. (Reuters)

are likely to newly qualify for semaglutide based on the drug's cardiovascular disease indication, researchers estimated. (Annals of Internal Medicine)

Stelo, the first , is now available for adults not using insulin, said maker Dexcom.

Ahead of a Senate committee hearing next month, Novo Nordisk's CEO of the company's blockbuster drug semaglutide, which ranges from $92 in the U.K. to $1,300 in the U.S. for a monthly supply of the weight-loss formulation. (NBC News)

Seven out of 25 treatment-naive patients with acromegaly had during the diagnostic oral glucose tolerance test, but a GIP receptor antagonist infusion eliminated this response in four patients. (Journal of Clinical Endocrinology & Metabolism)

The announced 14 leading endocrinologists as the winners of its 2025 Laureate Awards, the top honors in the field.

The FDA by Intarcia to reverse its rejection of the company's implant that delivers a GLP-1 agonist for type 2 diabetes, a product that agency advisors unanimously voted against last September. (Endpoints News)

A meta-analysis found that was tied to an increased incidence of type 2 diabetes. (Lancet Diabetes & Endocrinology)

A researcher at Mount Sinai Health System received a $4 million NIH grant to study the in metabolic health.

Does affect fertility? (Frontiers in Cellular and Infection Microbiology)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.